Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify (aripiprazole) oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: - schizophrenia - acute treatment of manic and mixed episodes associated with bipolar i disorder - adjunctive treatment of major depressive disorder - irritability associated with autistic disorder - treatment of tourette's disorder abilify injection is indicated for the treatment of: - agitation associated with schizophrenia or bipolar mania abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including abilify, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhea

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

otsuka pharmaceuticals (u.k. - aripiprazole - powder and solvent for suspension for injection - 400mg

Кенија - Енглески - Pharmacy and Poisons Board

claris otsuka private limited survey no. 199 to 201 & 208 to 210, village- - l-isoleucine usp l-leucine usp l-lysine… - solution for injection - 5%&10%w/v - intravenous solutions: solutions for parenteral

Египат - Енглески - EDA (Egyptian Drug Authority)

otsuka egypt - infusion

Египат - Енглески - EDA (Egyptian Drug Authority)

otsuka egypt - infusion

Египат - Енглески - EDA (Egyptian Drug Authority)

otsuka egypt - infusion

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

trigen laboratories, llc - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole is indicated for the treatment of: •schizophrenia [see clinical studies (14.1)] additional pediatric use information is approved for otsuka america pharmaceutical, inc.’s abilify® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)]. teratogenic effects pregnancy category c: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aripiprazole during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs (includi

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - tolvaptan, quantity: 15 mg - tablet - excipient ingredients: hyprolose; magnesium stearate; microcrystalline cellulose; indigo carmine aluminium lake; lactose monohydrate; maize starch - samsca is indicated for the treatment of clinically significant hypervolemic or euvolemic hyponatremia (serum sodium less than 125 mmol/l, or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction) including patients with heart failure and syndrome of inappropriate antidiuretic hormone (siadh).

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole tablets are indicated for the treatment of - schizophrenia - irritability associated with autistic disorder - treatment of tourette's disorder aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit  http://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs, including aripiprazole, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery (see clinical considerations) . overall availabl

Филипини - Енглески - FDA (Food And Drug Administration)

otsuka (phils.) pharmaceutical, inc.; distributor: macropharma corporation - glucose 15% (w/v) solution for iv infusion; amino acids 10% (wlv) '\.vtth electrolytes solution for intravenous injection; intravenous fat emulsion with medium and long chain triglycerides 20% emulsion for intravenous infusion - solution for iv infusion - see formulation on cpr